NCT04951947

JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer

A Prospective, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer With Previous Chemotherapy Combined With PD-L1 Failure

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Hunan Province Tumor Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.

Conditions

• Small-cell Lung Cancer

Interventions

Type	Name	Description
DRUG	JS201 combine with Lenvatinib	JS201 300mg i.v Q2wLenvatinib 8mg po. Qd

Timeline

• Start date: 2023-06-01
• Primary completion: 2024-12-01
• Completion: 2025-06-01
• First posted: 2021-07-07
• Last updated: 2024-09-19

Locations

1 site across 1 country: China